Sign in

    Colin Bristow • United States

    Colin Bristow is a Managing Director specializing in healthcare and biotechnology sector analysis, with recent coverage of major pharmaceutical companies such as Pfizer and an active presence in financial media. He has been noted for his in-depth assessments of drug development pipelines and market positioning, providing timely investment calls in high-profile therapeutic categories. Bristow serves as Managing Director at SIM IP and has previously held senior analyst roles, leveraging years of industry experience. His professional credentials include executive responsibilities and leadership in operational strategy within the finance sector.

    Colin Bristow's questions to BioXcel Therapeutics Inc (BTAI) leadership

    Colin Bristow's questions to BioXcel Therapeutics Inc (BTAI) leadership • Q1 2024

    Question

    Colin Bristow inquired about the timeline, cost, and specific FDA requirements for the 12-month safety data for the TRANQUILITY program in Alzheimer's agitation.

    Answer

    Executive Vincent O'Neill stated that while specific dates could not be provided, the timeline and cost for the TRANQUILITY In-Care study are expected to be very similar to the previous TRANQUILITY II trial. He confirmed that the 12-month safety data is a clear requirement and will be part of the sNDA package.

    Ask Fintool Equity Research AI

    Colin Bristow's questions to BioXcel Therapeutics Inc (BTAI) leadership • Q4 2023

    Question

    Asked about the potential timing and size of the TRANQUILITY trial, the sequential performance of IGALMI sales, and the timeline for an update on the credit agreement.

    Answer

    The company will provide details on the TRANQUILITY trial after receiving FDA minutes. IGALMI sales actually increased in Q4 vs Q3 due to the efforts of the small commercial team. Updates on the credit agreement will be provided as needed in collaboration with their partners.

    Ask Fintool Equity Research AI